Page URL:

Surgery with stem cells repairs eyes in clinical trial

4 February 2019
Appeared in BioNews 985

Stem cells taken from dead donors have been used to restore the damaged surface of the eye in a clinical trial, which researchers say is the first of its kind.

The study saw improvements with stem cell surgery in patients with limbal stem cell deficiency (LSCD), a disorder that can result in blindness.

'The findings from this small study are very promising and show the potential for safe stem cell eye surgery as well as improvements in eye repair,' said Professor Baljean Dhillon at the University of Edinburgh, who led the study.

'Our next steps are to better understand how stem cells could promote tissue repair for diseases that are extremely hard to treat and if, and how, they could help to restore vision.'

LSCD is a disorder where the stem cells which replenish the outermost layer of the cornea – the transparent covering at the front of the eye – are damaged or missing from the limbus, an area at the border of the cornea and the white sclera. Without the ability to repair this protective layer, redness, pain, scarring and vision loss may result.

Corneal transplantation is not an effective treatment for LSCD, but there have been studies where tissue transplants from healthy limbus tissue have replenished the cornea's protective layer. This tissue ideally comes from a healthy part of the patient's own eyes, to avoid the immune system rejecting it, but this is not an option for patients with LSCD affecting the entirety of both eyes.

In this study, tissue was taken from the limbus of recently deceased donors and cultivated on a membrane commonly used in eye surgery. Sixteen LSCD patients were then randomised to receive transplants of either the cultivated stem cells, or a control graft into the eye. All patients also received eye drops containing growth promoting chemicals taken from their own blood.

After 18 months, the patients receiving the stem cell transplants showed more improvement than the control patients on the 'ocular surface score', a measurement of how damaged the corneal surface is. This includes factors such as the transparency of the cornea, and the growth of unwanted blood vessels in the corneal tissue.

However, while some treated patients also showed improvement in visual function, this was also the case for the control patients, and could have been a result of the eye drops used.

The study was published in Stem Cells Translational Medicine.

20 January 2020 - by Emma Laycock 
A new study suggests that rare harmful mutations in young healthy donors' stems cells can be passed on to recipients of stem cell transplants, potentially leading to health problems...
9 September 2019 - by Shaoni Bhattacharya 
A team in Japan has successfully carried out the world's first transplant of corneal tissue made from human iPS cells...
14 May 2018 - by Paul Waldron 
The US Food and Drug Administration is seeking to shut down two clinics offering treatments based on stem cells...
9 April 2018 - by Caroline Casey 
A stem cell implant appears to be safe, suggest the results of a clinical trial for the dry form of age-related macular degeneration...
20 November 2017 - by Jenny Sharpe 
Preliminary results from two early stage clinical trials suggest that embryonic stem cells could be used to treat patients with dry age-related macular degeneration...
20 March 2017 - by Paul Waldron 
In two different attempts to treat degenerative eye diseases with stem cells, three patients have been blinded, while disease progression has been stopped in a separate patient...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.